Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 9:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–43 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Experienced Failure Clear all
Completed Phase 1 Interventional Results available

A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors

NCT03708328
View directory record Official record
Conditions
Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Esophageal Squamous Cell Carcinoma (ESCC)
Interventions
Lomvastomig
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Sep 4, 2026, 9:19 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Supporting Health in Veterans With Heart Failure

NCT05839067
View directory record Official record
Conditions
Heart Failure
Interventions
Care-HF
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
4
States / cities
Gainesville, Florida • Togus, Maine • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Sep 4, 2026, 9:19 AM EDT
Completed Phase 2 Interventional Results available

Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection

NCT04042740
View directory record Official record
Conditions
Hepatitis C Infection, HIV Infection
Interventions
Glecaprevir/Pibrentasvir (G/P)
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
11
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Sep 4, 2026, 9:19 AM EDT
Completed Phase 2 Interventional Results available

Pioglitazone for Lung Cancer Chemoprevention

NCT00780234
View directory record Official record
Conditions
Lung Cancer, Endobronchial Dysplasia
Interventions
fluorescence bronchoscopy, quantitative high resolution CT scan, PIOGLITAZONE VS. PLACEBO 30 mg
Procedure · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
2
States / cities
Denver, Colorado • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Sep 4, 2026, 9:19 AM EDT
Completed Not applicable Interventional

Improving Care of Patients With Heart Failure

NCT01461681
View directory record Official record
Conditions
Depression, Pain, Dyspnea, Quality of Life
Interventions
Symptom Management Service for Heart failure
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Sep 4, 2026, 9:19 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART

NCT00035581
View directory record Official record
Conditions
HIV Seropositivity, HIV Infection
Interventions
poly I-poly C12U
Drug
Lead sponsor
AIM ImmunoTech Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
7
States / cities
Fountain Valley, California • Norwalk, Connecticut • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Sep 4, 2026, 9:19 AM EDT
Completed Phase 3 Interventional Results available

SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection

NCT01962441
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF, RBV, Peg-IFN
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
23
States / cities
Riverside, California • San Diego, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Sep 4, 2026, 9:19 AM EDT
Completed Phase 3 Interventional

Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)

NCT00028301
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir, Lopinavir/Ritonavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2010 · Synced Sep 4, 2026, 9:19 AM EDT
Completed Phase 2 Interventional Results available

Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care

NCT01359644
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
PSI-7977, Daclatasvir, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
17
States / cities
Coronado, California • San Diego, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2015 · Synced Sep 4, 2026, 9:19 AM EDT
Recruiting No phase listed Observational

Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy

NCT01834001
View directory record Official record
Conditions
Prostatic Neoplasms, Prostate Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 4, 2026, 9:19 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects

NCT01726517
View directory record Official record
Conditions
Chronic Hepatitis C Virus
Interventions
LDV/SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 4, 2026, 9:19 AM EDT
Completed Not applicable Interventional

Interventions to Improve Daily Activity in Heart Failure

NCT02331524
View directory record Official record
Conditions
Heart Failure
Interventions
Activity Feedback and Encouragement, Health Coaching/Home Exercise
Behavioral · Other
Lead sponsor
Grand Valley State University
Other
Eligibility
40 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 4, 2026, 9:19 AM EDT
Completed Not applicable Interventional Results available

Evaluation of the Immune Response to Clostridium Difficile in Adults With Clostridium Difficile Infection (CDI)

NCT01716533
View directory record Official record
Conditions
Infections, Clostridium Difficile
Interventions
Blood sampling, Stool sample collection
Procedure · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Little Rock, Arkansas • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Sep 4, 2026, 9:19 AM EDT
Completed No phase listed Observational

A Study of Prevalence of the I50L Mutation When ATV Treated Patients Fail the Regimen

NCT00135447
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
84
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 58 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2011 · Synced Sep 4, 2026, 9:19 AM EDT
Completed Phase 1 Interventional

Safety and Efficacy Study of Etanercept (Enbrel) on the Response Rate of HIV-infected Subjects

NCT00091741
View directory record Official record
Conditions
HIV Infection
Interventions
Etanercept (Enbrel)
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 21, 2009 · Synced Sep 4, 2026, 9:19 AM EDT
Completed Phase 3 Interventional Results available

A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT

NCT00727597
View directory record Official record
Conditions
Human Immunodeficiency Virus Infections
Interventions
Efavirenz 600mg, Boosted Lexiva
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Sep 4, 2026, 9:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC

NCT00602030
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma, Carcinoma, Non-Small Cell Lung
Interventions
Entinostat, Placebo, Erlotinib
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
30
States / cities
Tucson, Arizona • Denver, Colorado • Miami, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Sep 4, 2026, 9:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Coping in Heart Failure Partnership Intervention

NCT05337293
View directory record Official record
Conditions
Heart Failure
Interventions
COPE-HF Partnership Intervention, Attention
Behavioral · Other
Lead sponsor
Florida State University
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Sep 4, 2026, 9:19 AM EDT
Terminated Phase 2 Interventional Results available

Emtricitabine/Tenofovir Alafenamide as Salvage ART

NCT02556333
View directory record Official record
Conditions
HIV
Interventions
FTC/TAF
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
14 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Sep 4, 2026, 9:19 AM EDT